Search Results 681-690 of 18066 for Alopecia

1. Abiraterone/Prednisone, Olaparib, Or Abiraterone/Prednisone + Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects - Mayo Clinic

   Persistent toxicities (≥CTCAE Grade 2), with the exception of alopecia, caused by previous cancer therapy. Resting ECG with QTc > 470msec on 2 or more time ...

2. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

   Participation eligibility · Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. · Has ...

3. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma - Mayo Clinic

   ... alopecia, fatigue. For patients enrolling on Cohort A or Cohort B: For patients treated with surgery, an interval of >= 21 days must have elapsed prior to ...

4. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia). Age 18 years ...

5. Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 ...

6. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   ... alopecia;; Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is ...

7. IFX_HU2.0 As An Adjunctive Therapy To Pembrolixumab In Checkpoint Inhibitor Naive Subjects With Advanced Or Metastatic Merkel Cell Carcinoma - Mayo Clinic

   ... alopecia) not requiring systemic treatment are permitted to enroll. Low grade autoimmune toxicity is NOT an exclusion under this criterion. Subjects with ...

8. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Toxic effects of prior anti-cancer therapy considered as chronic, such as chemotherapy-induced fatigue, alopecia, or anorexia of ≤ Grade 2, where no more ...

9. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   ... alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin ...

10. A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer - Mayo Clinic

    alopecia. Exclusion Criteria: - Tumors in the breast or bone - Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy ...